FORMULATION AND DEVELOPMENT OF LINAGLIPTIN-LOADED SUBLINGUAL FILMS: A COMPREHENSIVE REVIEW

G. M. WADHANKAR[1*], D. L. BAWANKAR[1], S. W. LOHE[1], R. L. KUMARE[1], P. S. CHUDHARI[1], S. G. THULE[1]
1*,1 - Anurag College of Pharmacy, Warthi, Bhandara-441905 (M.S.)
*Corresponding Author
Email: gauravwadhankar2002@gmail.com
Received: 25th May, 2026; **Revised:** 6th June, 2026; **Accepted:** 8th June, 2026; **Available Online:** 09th June, 2026

ABSTRACT
The sublingual drug formulations offer a fast and non-invasive approach for the conventional oral tablet drugs, leading to improved bioavailability and patient compliance. This approach is especially beneficial for antidiabetic medical agents, such as linagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the treatment of type 2 diabetes mellitus. The positive characteristics of the pharmacokinetic profile of linagliptin, weak hepatic metabolism, higher protein binding and low renal clearance (renal secretion is the major route) further support its appropriateness for sublingual administration, leading to a bypass of first-pass and providing faster systemic exposure. The present review discusses the literature, recent advances in linagliptin SFs, including formulation design strategy, polymer selection, and advanced manufacturing technologies. Other critical parameters like film-forming polymers, plasticisers, mucoadhesive agents, as well as solubility enhancers, are also presented with preparation methods of solvent casting, hot-melt extrusion and currently new, fledgling technology of electrospinning. Quality attributes, including mechanical strength, disintegration time, mucoadhesion, drug release kinetics and stability, are also described to give an overview of the quality aspect. These include the potential of latest technological breakthroughs, such as nanofiber film-based films, mucoadhesive bio-compatible biopolymers and surface-modified drug carriers for an enhanced therapeutic performance. Challenges in mass production, regulatory concerns, and long-term stability are still some of the main obstacles for clinical translation. The landscape for patient-centred sublingual delivery is promising as an alternative approach to personalised diabetes care, including rapid onset of action, enhanced convenience, and superior therapeutic outcomes compared to conventional oral formulations. In conclusion, linagliptin-loaded sublingual films constitute an emerging area of investigation that could revolutionise the concept of contemporary antidiabetic therapy.
KEYWORDS: Linagliptin, Sublingual films, Formulation development, Rapid disintegrating films, Bioavailability enhancement, Formulation development
How to cite this article: Wadhankar GM, Bawankar DL, Lohe SW, Kumare RL, Chudhari PS, Thule SG. Formulation and Development of Linagliptin-Loaded Sublingual Films: A Comprehensive Review. Int J Drug Deliv Technol. 2026;16(64s):1396-1406. DOI: 10.25258/ijddt.16.64s.146

Source of support: Nil.
Conflict of interest: None

INTRODUCTION

Despite the widespread availability of oral antidiabetic medications, their therapeutic efficiency is frequently hampered by variable gastrointestinal absorption, substantial hepatic first-pass metabolism, and poor patient adherence, especially in the elderly and multi-medicated patients. Linagliptin, a strong and selective DPP-4 inhibitor [1], has notable pharmacokinetic advantages over other gliptins, including negligible renal excretion, extraordinarily high plasma protein binding (~80%), and a prolonged half-life [2], allowing for once-daily administration [3]. However, presystemic clearance limits even linagliptin's bioavailability when taken as standard oral tablets, requiring greater dosages and postponing its glucose-lowering action [4]. These pharmacological characteristics, along with its favourable lipophilicity and modest therapeutic dose of 5 mg, make linagliptin a very sensible option for transmucosal administration, where the rich oral cavity vasculature can be used to get across the hepatic barrier [5].

Sublingual drug delivery has gained attention as a patient-friendly and non-invasive way to address these barriers. The area under the tongue is rich in blood vessels [6], allowing medications to be absorbed directly into the bloodstream while bypassing the liver [7]. This results in a faster onset of action, reduced dosage requirements, and more predictable therapeutic effects, which is especially helpful for elderly patients or those who struggle with swallowing pills [8].

Among the different sublingual dosage forms, fast-dissolving films have become particularly promising [9]. These thin, flexible films dissolve almost instantly upon contact with saliva, releasing the drug efficiently without requiring water [10]. Their portability, discreet use, and ease of administration make them ideal for a wide range of patients, including those who need assistance from caregivers. Modern manufacturing techniques such as solvent casting, hot-melt extrusion, and electrospinning allow precise control over film thickness, drug distribution, and dissolution behaviour, enabling customisation of film formulations according to individual patient needs.

Recent studies on sublingual films for antidiabetic agents like linagliptin have shown impressive improvements in their performance. Delivering linagliptin through sublingual films can increase bioavailability by up to three times and produce faster glucose-lowering effects, making this approach particularly useful for controlling post-meal blood sugar spikes. Drug absorption occurs mainly through passive diffusion across the thin mucosal layers into nearby blood vessels. Drug properties such as lipophilicity, solubility, molecular size, and pKa play an important role in how efficiently they cross the sublingual membrane. Linagliptin's characteristics make it well-suited for this type of absorption. To further enhance performance, formulations often incorporate mucoadhesive polymers, permeation enhancers, and solubility-boosting additives to improve how much drug is absorbed and how long it stays in contact with the mucosa.

For these films to be effective, they must meet several quality criteria. They should dissolve quickly, be strong yet flexible, maintain a neutral surface pH, deliver uniform drug content, adhere well to mucosal tissues, release the drug at a predictable rate, and remain stable during storage. Polymers such as HPMC, PVA, and PVP paired with plasticisers like PEG or glycerol help achieve the right blend of strength, flexibility, and rapid dissolution. Advanced technologies like electrospinning can produce nanofiber-based films with extremely high surface areas, which significantly enhance dissolution and improve drug permeation through the mucosa. Similarly, mucoadhesive biopolymers and nanocarrier-based systems have been explored to prolong film residence time and further increase bioavailability.

Table 1. Comparative Overview: Conventional Oral Linagliptin Tablet vs. Linagliptin Sublingual Film

Sr. No.	Parameter	Conventional Oral Tablet (Tradjenta®)	Linagliptin Sublingual Film (Proposed)
1	Dose Strength	5 mg (fixed dose, once daily)	5 mg (current research focus); potentially reducible to 2.5–3 mg in future due to enhanced absorption
2	First-Pass Metabolism	Extensive (hepatic metabolism via CYP3A4 and renal excretion)	Bypassed (drug directly enters systemic circulation via the internal jugular vein)
3	Time to Peak Plasma Concentration (T_{max})	~1.5–2 hours (90–120 min)	~10–15 minutes (ultra-rapid absorption)
4	Absolute Bioavailability	~30%	Projected ~60–80% (based on 2.5–3× higher C_{max} observed in preclinical models)
5	Onset of Therapeutic Action	Slow (2–4 hours); primarily manages basal glucose	Rapid (15–30 min); highly effective for postprandial (post-meal) glucose spikes
6	Ease of Administration	Requires water for swallowing; difficult for patients with dysphagia or while travelling	No water required; dissolves in seconds; discreet and portable

7	Patient Suitability	General Type 2 Diabetes Mellitus (T2DM) population	Ideal for elderly, paediatric, neurologically impaired patients, those with nausea/vomiting, or patients requiring rapid glycemic correction

Despite significant progress, certain challenges persist. Scaling up film production for commercial use requires strict control to ensure uniform dosing and consistent quality, which can be difficult to achieve. Since these films are sensitive to moisture, specialised packaging and comprehensive stability testing are essential to maintain their effectiveness over time. Additionally, differences in saliva production, oral physiology, and handling techniques among patients can influence how well the drug is absorbed, emphasising the need for thorough clinical evaluation.

Even with these obstacles, the future of sublingual drug delivery for diabetes management looks highly promising. Sublingual films offer rapid action, greater convenience, and improved patient adherence—benefits that are particularly important for individuals who need quick blood sugar control or who have trouble swallowing tablets. Meanwhile, new technologies such as electrospinning, nanotechnology, and 3D printing are opening doors for personalised medicine, allowing sublingual films to be tailored to the unique needs of each patient. As formulation science, material engineering, and regulatory frameworks continue to evolve, linagliptin-loaded sublingual films are positioned to play a major role in the next generation of diabetes treatment.



Figure 1: Sublingual Mucosal Anatomy and Drug Permeation Pathways

2. FORMULATION SCIENCE OF LINAGLIPTIN SUBLINGUAL FILMS

2.1 Formulation Rationale

The development of linagliptin-loaded sublingual films is driven by the need for a rapid, user-friendly alternative to conventional oral antidiabetic therapy. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is particularly well-suited for transmucosal delivery due to its low therapeutic dose (5 mg), favourable solubility in mildly acidic to neutral pH, and a pKa of approximately 8.6—features that enable rapid ionisation in the oral environment. These physicochemical attributes support faster dissolution and potentially faster onset of action compared to oral tablets, which undergo extensive first-pass metabolism.

However, crafting an effective sublingual film requires a delicate balance between fast disintegration, mechanical stability, and dose uniformity. To ensure both performance and patient acceptability, a linagliptin sublingual film should ideally exhibit:

- Rapid disintegration within 20–30 seconds
- Adequate tensile strength and flexibility for safe handling
- Uniform drug distribution across every unit
- Surface pH between 6.5–7.0 to prevent mucosal irritation
- Mucoadhesion for 2–5 minutes, allowing sufficient drug permeation

These attributes can be achieved only through the strategic selection of polymers, plasticizers, permeation enhancers, saliva stimulants, and taste-masking agents.

2.2 Polymer and Excipient Selection

The polymer matrix is the foundational component of sublingual films, defining their mechanical strength, dissolution rate, flexibility, and overall mouthfeel. Several polymers are commonly used to formulate rapid-dissolving or mucoadhesive films [11,12]:

- Hydroxypropyl methylcellulose (HPMC E5/E15) – ensures quick dissolution and smooth film texture
- Pullulan – forms transparent, elegant films with excellent taste
- Polyvinyl alcohol (PVA) – provides strength and enhances durability
- Sodium alginate, CMC, PVP K-30 – improve swelling, mucoadhesion, and drug release behaviour

To prevent brittleness and cracking, plasticizers are incorporated, typically in the range of 10–30% w/w of the polymer mass:

- Glycerol
- PEG-400
- Propylene glycol

Because the sublingual mucosa can offer resistance to drug permeation, excipients like Tween-80, Oleic acid, Menthol, and Sodium lauryl sulphate enhance bilayer permeability [13,14]. Sensory acceptability is improved using sweeteners (sucralose, mannitol), flavours (peppermint, mint), and saliva stimulants such as citric or malic acid, which accelerate film hydration.

Table 2. Typical Composition of a Linagliptin Sublingual Film

Sr. No.	Ingredient Class	Examples	Typical Quantity
1	API (Active Pharmaceutical Ingredient)	Linagliptin	5 mg per film
2	Film-forming Polymers	HPMC (E5/E15), Pullulan, PVA, Sodium alginate, PVP K-30, HEC	40–60%
3	Plasticizers	PEG-400, Glycerol, Propylene glycol, Sorbitol, Triethyl citrate	10–20%
4	Saliva Stimulants	Citric acid, Malic acid, Tartaric acid, Ascorbic acid	2–5%
5	Permeation Enhancers	Tween-80, Oleic acid, Menthol, Sodium lauryl sulphate (SLS), Chitosan	0.5–2%
6	Sweeteners	Sucralose, Mannitol, Aspartame, Xylitol, Sodium saccharin	2–4%
7	Flavouring Agents	Peppermint oil, Spearmint, Vanillin, Orange oil, Cherry flavour	1–2%
8	Solvents	Purified water, Ethanol, Isopropanol, Hydroalcoholic mixtures	q.s.

3. MANUFACTURING METHODS FOR LINAGLIPTIN SUBLINGUAL FILMS

3.1 Solvent Casting Method

Procedure

In this widely used technique, the polymer is first dissolved in water or a hydroalcoholic medium and allowed to hydrate. A plasticiser is added to increase film elasticity, followed by linagliptin, which is pre-dissolved in a compatible solvent. The mixture is homogenised and degassed to remove trapped air. The prepared solution is cast on a flat surface, dried at 40–45 °C, and then cut into uniform films before packaging [15,16].

Advantages

- Produces films with uniform thickness and smooth appearance
- Requires inexpensive equipment
- Ideal for heat-sensitive drugs like linagliptin
- Easy to implement at small to medium production scales

Disadvantages

- Requires long drying times
- Risk of residual solvent retention
- Sensitive to humidity fluctuations, which can cause film curling or cracking

Limitations

- Not efficient for poorly soluble drugs
- Limited suitability for high-volume industrial production

3.2 Hot-Melt Extrusion (HME)

Procedure

In HME, linagliptin, polymer, and excipients are melted in an extruder at a controlled temperature (80–140 °C) and continuously mixed by rotating screws. The molten mixture is forced through a slit die to form a thin sheet, which is cooled and cut into films [17,18].

Advantages

- Completely solvent-free
- Excellent content uniformity due to intense mixing
- Highly scalable for continuous industrial operations
- Faster processing than solvent casting

Disadvantages
- Risk of thermal degradation of the drug or excipients
- Requires expensive machinery and skilled operators
- Taste and volatile components may degrade or evaporate

Limitations
- Inappropriate for heat-labile materials
- Limited compatibility with certain flavours and thermosensitive polymers

Importantly, the processing temperatures typically used in HME (80–140 °C) make this method a safe, practical, and solvent-free alternative for producing linagliptin films, given linagliptin's thermal stability up to about 200 °C.

3.3 Electrospinning

Procedure

A high voltage is applied to a polymer–drug solution, creating ultrafine fibers that deposit onto a collector to form a non-woven mat. After solvent evaporation, the fibers are shaped into films [19,20].

Advantages
- Produces ultra-fast dissolving films (5–10 seconds)
- Extremely high surface area enhances dissolution
- Can improve the solubility of poorly soluble drugs

Disadvantages
- Requires volatile organic solvents
- Resulting films may be mechanically weak
- Low throughput and slow productivity

Limitations
- Difficult to scale for commercial production
- High equipment and operational costs

Although the exceptionally quick disintegration (5–10 seconds) is very beneficial for attaining a nearly instantaneous initiation of action, this feature needs to be carefully weighed against the intrinsic mechanical fragility of electrospun nanofibrous mats. To avoid structural damage during handling, shipping, and storage, this fragility frequently calls for the adoption of specialized, protective packaging (such as hard blister foils or laminated pouches).

3.4 3D Printing / Additive Manufacturing

Procedure

Digital models guide the controlled deposition of drug-loaded inks or polymer filaments. Linagliptin is incorporated precisely into the printed layers to create films with defined geometry, thickness, and dose [21].

Advantages
- Enables personalised dosing
- Excellent reproducibility
- Allows designing films with complex structures or multi-drug layers

Disadvantages
- Slow printing speed
- Requires specialised materials and equipment
- Optimisation of ink viscosity and flow is critical

Limitations
- Limited regulatory clarity for pharmaceutical 3D printing
- Potential risks of dose non-uniformity

3.5 Freeze-Drying (Lyophilisation)

Procedure

The film-forming solution is cast into molds and frozen. The frozen structure undergoes sublimation under vacuum, leaving behind a porous, sponge-like film [22].

Advantages
- Produces films with extremely rapid hydration
- Suitable for heat-sensitive drugs
- Enhanced dissolution due to micro-porous structure

Disadvantages
- Very expensive equipment
- High energy consumption
- Films are often fragile and require specialised packaging

Limitations
- Poorly suited for large-scale production
- Long processing cycles limit throughput

3.6 Supercritical Fluid Processing

Procedure

Supercritical CO_2 is used as a green solvent to dissolve polymers and drugs under high pressure. When pressure is released, CO_2 escapes rapidly, forming micro-porous films with uniformly distributed linagliptin [22].

Advantages
- Environmentally friendly
- No organic solvent residues
- Allows precise control of porosity and film morphology

Disadvantages
- Requires costly high-pressure equipment
- Complex processing conditions
- Requires highly trained personnel

Limitations
- Limited commercialization; mostly in the research phase

- Not cost-effective for routine pharmaceutical production

Table 3. Comparative Summary of Techniques

Sr. No.	Method	Cost	Scalability	Uses Solvent	Film Quality	Disintegration Speed
1	Solvent Casting	Low	Medium	Yes	Good	20–30 s
2	Hot-Melt Extrusion	Moderate	High	No	Excellent	15–25 s
3	Electrospinning	High	Low	Yes	Excellent	5–10 s
4	3D Printing	High	Medium	Minimal	High	Variable
5	Freeze-Drying	Very High	Low	Minimal	Very Good	10–15 s
6	Supercritical CO_2	Very High	Low	No	High	10–20 s

4. EVALUATION AND CHARACTERIZATION OF LINAGLIPTIN SUBLINGUAL FILMS

Evaluating linagliptin sublingual films is a crucial step in ensuring that every batch delivers fast, safe, and reliable therapy. Because these films are designed to dissolve quickly under the tongue and bypass first-pass metabolism, they must meet strict physical, mechanical, and biological quality standards. The following assessments help confirm that the films are uniform, stable, easy to handle, and capable of providing rapid systemic absorption.

4.1 Physical and Mechanical Evaluation

The first set of tests focuses on the basic physical features of the films.

- Thickness and weight variation are measured using a digital micrometre at different points on each film. Keeping variation within ±5% helps guarantee consistent dosing and reliable drug release across all units.
- To assess durability, formulators perform a folding endurance test, where the film is repeatedly folded at the same spot until it breaks. Films that withstand more than 200 folds are considered mechanically robust and suitable for routine handling and packaging [23].
- Mechanical strength is further explored using texture analysis, which measures tensile strength and percent elongation. This ensures each film is strong enough not to tear easily but flexible enough to avoid cracking during use [24].
- Another important parameter is surface pH, measured by lightly moistening the film and placing a pH electrode on its surface. A pH between 6.5 and 7.5 mimics physiological oral pH and prevents irritation, particularly important for sensitive mucosal tissues [24].
- Since sublingual films readily interact with moisture, they are evaluated for moisture content and moisture uptake. Too much moisture can weaken the structure or degrade the drug, whereas too little can make films brittle and uncomfortable to handle.

4.2 Drug Content Uniformity

Drug content uniformity ensures that every film delivers the intended dose. A small piece of the film—commonly 2 × 2 cm—is dissolved in phosphate buffer and analysed using UV-visible spectrophotometry at 299 nm. Regulatory standards require the drug content to lie within 85–115% of the label claim. This test is especially important because solvent-cast films may experience drug migration during drying if not properly optimized [24].

4.3 Disintegration and Dissolution

Fast disintegration is one of the defining characteristics of sublingual films. To evaluate this, films are exposed to simulated saliva in a petri dish or using a modified USP disintegration apparatus. Linagliptin films typically disintegrate in under 30 seconds, ensuring rapid onset of action [25].

Dissolution testing is conducted using the USP type II paddle apparatus at 37°C. Most well-designed formulations release over 90% of the drug within 10–15 minutes, reflecting the high solubility of linagliptin and the hydrophilic nature of polymers like HPMC. The drug release profile commonly fits Higuchi diffusion or first-order kinetics, indicating predictable release performance [26,27].

4.4 *In-Vitro* Release Kinetics

Release kinetics are primarily based on the Higuchi model, which indicates diffusion-controlled drug release from the polymeric matrix. The Korsmeyer-Peppas model produces a 'n' value greater than 0.5, supporting a non-Fickian (anomalous) transport mechanism in which release is driven by a mix of polymer swelling and drug diffusion, as is typical of hydrophilic film-forming polymers such as HPMC [28,29,30].

4.5 *Ex-Vivo* Permeation Studies

To understand how efficiently the drug can pass through the sublingual mucosa, *ex-vivo* permeation studies are performed using Franz diffusion cells. Porcine or goat sublingual tissue is mounted between the donor and receptor compartments. The film is placed on the tissue, and samples from the receptor chamber are collected over time for analysis.

From these data, researchers calculate essential parameters like steady-state flux (Jss) and permeability coefficient (Kp) using Fick's law. Films containing surfactants such as Tween-80 often show improved permeation by enhancing membrane fluidity and improving drug partitioning [31,32,33].

4.6 Mucoadhesion and Residence Time

Mucoadhesion determines how well the film adheres to the sublingual mucosa. Using balance methods or texture analysers, the force needed to detach the film from mucosal tissue is measured. Ideally, the film adheres for 2–5 minutes, enough to facilitate effective absorption without causing discomfort [34,35].

4.7 Thermal and Spectroscopic Characterisation

A combination of analytical techniques ensures compatibility and stability:

- Differential Scanning Calorimetry (DSC) reveals whether the drug has transitioned to an amorphous form within the film [36].
- FTIR spectroscopy checks for chemical interactions by analysing characteristic peaks; minimal peak shifts indicate good compatibility [37].
- X-Ray Diffraction (XRD) confirms reduced crystallinity, often associated with faster dissolution and improved bioavailability [38].
- SEM imaging provides detailed surface morphology, confirming a smooth, uniform film without cracks or crystal clusters [39].

These evaluations collectively ensure that the structural and chemical integrity of the film is maintained throughout its shelf life.

4.8 *In-Vivo* Pharmacokinetics

In-vivo studies demonstrate the real-world performance of linagliptin sublingual films. Because the drug is absorbed directly into systemic circulation, T_{max} occurs within 10–15 minutes, much quicker than standard tablets. Peak plasma concentrations (C_{max}) are 2.5–3 times higher, reflecting bypassing of first-pass metabolism [40,41].

Therapeutic plasma levels remain stable for up to 12 hours, supporting the potential of sublingual delivery for improved glycemic control.

4.9 Clinical Implications

The fast onset of action makes linagliptin sublingual films especially useful for:

- Managing postprandial glucose spikes
- Emergency glycemic correction
- Patients with dysphagia, including elderly or neurologically impaired individuals

Recent work on linagliptin–metformin nanoparticle combination films suggest enhanced glycemic control with fewer gastrointestinal side effects, presenting a promising strategy for future diabetes care.

4.10 Stability Studies

Stability testing is critical to determine how well the films withstand environmental stress. Both real-time (25°C/60% RH) and accelerated (40°C/75% RH) conditions are used. Parameters monitored include:

- Appearance
- Folding endurance
- Drug content
- Disintegration time
- Crystallinity

Degradation levels below 5% after six months indicate good stability. Moisture-proof packaging—such as alu-alu blisters and laminated pouches—is essential to prevent film softening or drug degradation during storage.

5. REGULATORY CONSIDERATIONS

Regulatory authorities, such as the FDA and EMA, mandate compliance with the ICH Q8 (Quality-by-Design) [42], Q9 (Risk Management) [43], and Q10 (Quality Systems) [44] frameworks throughout the development process. Different from oral disintegrating tablets (ODTs), sublingual films are categorised as mucosal drug products and are subject to strict production, quality, and safety requirements.

Quality Standards (USP): USP <701> for disintegration, which mandates full film disintegration in less than 30 seconds, governs performance. For solvent-cast films that are susceptible to drug migration, uniformity of dosage units per USP <905> requires an Acceptance Value (AV) of ≤ 15.0, with individual drug content lying between 75–125% of the label claim [46].

Mucosal Safety: Local toxicity testing is essential due to the direct administration to the oral mucosa. In addition to typical irritation and tolerance investigations, submission packages must contain a histological study of sublingual/buccal tissues to rule out cellular injury, inflammation, or epithelial erosion.

Packaging & Stability: Films need protective packaging, usually alu-alu blisters or laminated pouches, because of their extreme moisture sensitivity. In order to preserve

stability and GRASE (generally acknowledged as safe and effective) status, such dosage forms must be in single-unit or unit-dose containers, according to recent FDA draft advice (OTC000037) [47].

CMC & Regulatory Pathway: The FDA's 505(b)(2) approach is feasible for generic or modified formulations as long as solid bioequivalency findings are presented. Under cGMP-compliant settings, the Chemistry, Manufacturing, and Controls (CMC) department must meticulously record film thickness, content homogeneity, dissolution profiles, and validated drying processes to guarantee batch-to-batch consistency and little residual solvents [45].

6. FUTURE PERSPECTIVES

The sublingual route imposes a strict anatomical ceiling, despite the hype. A significant portion of the dissolved medication is simply swept into the throat and swallowed due to the films' useable absorptive surface of only 2 cm^2 and steady salivary flush of 0.3–0.5 mL/min, which reinstates the very first-pass metabolism these films are intended to avoid. Because of this, formulators are forced to make an annoying trade-off: the film must adhere strongly enough to withstand washout while disintegrating swiftly enough for patients to bear it. This tension is simply not reliably resolved by current polymers.

The translational barriers do not end at the tissue. It is infamously difficult to establish significant IVIVC for mucoadhesive, fast-dissolving materials since human plasma profiles are rarely properly predicted by what functions in a Franz cell. Regulators are aware of this, which drives developers to conduct expensive, high-risk pharmacokinetic experiments that few financiers are willing to sponsor. In addition, the economics are sobering: 3D printers, electrospinning machines, and moisture-proof blister packing are expensive. The very accessibility that first made sublingual films appealing will be undermined by these expenses, which will ultimately fall on the patient's pocket [48,49].

It takes more than just sophisticated polymer science to get these films onto drugstore shelves. We require physiologically relevant screening instruments that truly replicate the dynamic oral environment, truly salivary-resistant bioadhesives, and scale-up strategies that don't drive firms into bankruptcy. Linagliptin sublingual films won't revolutionize the treatment of diabetes without these useful discoveries; instead, they will continue to be an intriguing research project.

7. CONCLUSION

Linagliptin sublingual films represent a promising shift in the management of type 2 diabetes, especially for patients who struggle with conventional oral tablets or require faster therapeutic action. By delivering the drug directly through the sublingual mucosa, these films bypass first-pass metabolism, allowing for quicker onset, enhanced bioavailability, and often a lower required dose. This not only improves treatment efficiency but also makes daily medication routines more comfortable and less burdensome. Recent advancements in polymer science and nanotechnology have significantly improved the mechanical strength, stability, and drug-release characteristics of these films. Modern manufacturing techniques such as solvent casting, hot-melt extrusion, and nano-enhanced film incorporation are making production more consistent, scalable, and patient-centric. Researchers are also exploring biodegradable materials and green-chemistry approaches to make these films safer for both patients and the environment. Beyond their technical advantages, sublingual films hold meaningful value in real-world clinical settings. They can benefit elderly patients with swallowing difficulties, individuals with busy lifestyles who need discreet dosing, and those requiring rapid glycemic control. With the growing momentum toward personalized medicine, these films could eventually be tailored in terms of strength, flavour, size, and dissolution rate to better match individual patient needs. As ongoing research continues to refine formulation strategies and evaluate long-term safety, linagliptin sublingual films are expected to develop into smarter, more adaptable drug-delivery platforms. Their potential to improve patient comfort, adherence, and therapeutic outcomes compelling therapeutic alternative for the future of diabetes care.

8. REFERENCES

1. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes, Obesity and Metabolism. 2011 Jan;13(1):7-18.
2. Retlich S, Duval V, Graefe-Mody U, Jaehde U, Staab A. Impact of target-mediated drug disposition on linagliptin pharmacokinetics and DPP-4 inhibition in type 2 diabetic patients. The Journal of Clinical Pharmacology. 2010 Aug;50(8):873-85.
3. Freeman MK. Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus. Pharmacy and Therapeutics. 2011 Dec;36(12):807.

4. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clinical pharmacokinetics. 2012 Jul;51(7):411-27.
5. Scott LJ. Linagliptin: in type 2 diabetes mellitus. Drugs. 2011 Mar;71(5):611-24.
6. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. JNCI Monographs. 2001 Oct 1;2001(29):7-15.
7. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. Journal of controlled release. 2011 Jul 30;153(2):106-16.
8. Holpuch AS, Hummel GJ, Tong M, Seghi GA, Pei P, Ma P, Mumper RJ, Mallery SR. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharmaceutical research. 2010 Jul;27(7):1224-36.
9. Dixit RP, Puthli SP. Oral strip technology: Overview and future potential. Journal of controlled release. 2009 Oct 15;139(2):94-107.
10. Hoffmann EM, Breitenbach A, Breitkreutz J. Advances in orodispersible films for drug delivery. Expert opinion on drug delivery. 2011 Mar 1;8(3):299-316.
11. Alhamhoom Y, Sharma A, Nanjappa SH, Kumar A, Alshishani A, Ahmed MM, Farhana SA, Rahamathulla M. Development and evaluation of solid dispersion-based sublingual films of nisoldipine. Pharmaceuticals. 2023 Nov 9;16(11):1589.
12. Karki S, Kim H, Na SJ, Shin D, Jo K, Lee J. Thin films as an emerging platform for drug delivery. Asian journal of pharmaceutical sciences. 2016 Oct 1;11(5):559-74.
13. Williams AC, Barry BW. Penetration enhancers. Advanced drug delivery reviews. 2012 Dec 1;64:128-37.
14. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci. 1998 Jan 1;1(1):15-30.
15. Borges AF, Silva C, Coelho JF, Simões S. Oral films: current status and future perspectives: I—galenical development and quality attributes. Journal of Controlled Release. 2015 May 28;206:1-9.
16. Preis M, Knop K, Breitkreutz J. Mechanical strength test for orodispersible and buccal films. International journal of pharmaceutics. 2014 Jan 30;461(1-2):22-9.
17. Repka MA, Battu SK, Upadhye SB, Thumma S, Crowley MM, Zhang F, Martin C, McGinity JW. Pharmaceutical applications of hot-melt extrusion: Part II. Drug development and industrial pharmacy. 2007 Jan 1;33(10):1043-57.
18. Cilurzo F, Cupone IE, Minghetti P, Selmin F, Montanari L. Fast dissolving films made of maltodextrins. European Journal of pharmaceutics and Biopharmaceutics. 2008 Nov 1;70(3):895-900.
19. Bhardwaj N, Kundu SC. Electrospinning: A fascinating fiber fabrication technique. Biotechnology advances. 2010 May 1;28(3):325-47.
20. Vedanayagam S, Selvaraj R, Kanniyappan H, Mathew MT, Doble M, Perumal G. Nanofibers loaded levosalbutamol sulfate fast dissolving oral films for sublingual delivery. Journal of Drug Delivery Science and Technology. 2024 Sep 1;99:105920.
21. Norman J, Madurawe RD, Moore CM, Khan MA, Khairuzzaman A. A new chapter in pharmaceutical manufacturing: 3D-printed drug products. Advanced drug delivery reviews. 2017 Jan 1;108:39-50.
22. Parhi R, Suresh P. Supercritical fluid technology: A review. Journal of Advanced Pharmaceutical Science and Technology. 2013 Jan 30;1(1):13-36.
23. Bhupinder B, Sarita J. Formulation and evaluation of fast dissolving sublingual films of Rizatriptan Benzoate. Int J Drug Dev Res. 2012 Jan;4(1):133-43.
24. Kannuri R, Challa T, Chamarthi H. Taste masking and evaluation methods for orodispersible tablets. Int J Pharm Ind Res. 2011;1(3):201-10.
25. Bhattacharyya L, Cecil T, Dabbah R, Roll D, Schuber S, Sheinin EB, Williams RL, USP Council of Experts Executive Committee. The value of USP public standards for therapeutic products. Pharmaceutical research. 2004 Oct 1;21(10):1725.
26. Gupta P, Patel DH, Dhameliya N, Modh P, Joshi V. A review on dissolution method development for drug products: Current regulations and prospects. Research Journal of Pharmaceutical Dosage Forms and Technology. 2023 Nov 9;15(4):293-.
27. Garsuch V, Breitkreutz J. Comparative investigations on different polymers for

the preparation of fast-dissolving oral films. Journal of Pharmacy and Pharmacology. 2010 Apr;62(4):539-45.
28. Higuchi TJ. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. Journal of pharmaceutical sciences. 1963 Dec;52(12):1145-9.
29. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. International journal of pharmaceutics. 1983 May 1;15(1):25-35.
30. Siepmann J, Peppas NA. Higuchi equation: Derivation, applications, use and misuse. International journal of pharmaceutics. 2011 Oct 10;418(1):6-12.
31. Shojaei AH, Berner B, Li X. Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport. Pharmaceutical research. 1998 Aug;15(8):1182-8.
32. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. European journal of Pharmaceutics and Biopharmaceutics. 2001 Mar 1;51(2):93-109.
33. Nicolazzo JA, Reed BL, Finnin BC. Buccal penetration enhancers—how do they really work?. Journal of controlled release. 2005 Jun 20;105(1-2):1-5.
34. Smart JD. The basics and underlying mechanisms of mucoadhesion. Advanced drug delivery reviews. 2005 Nov 3;57(11):1556-68.
35. Khutoryanskiy VV. Advances in mucoadhesion and mucoadhesive polymers. Macromolecular bioscience. 2011 Jun 14;11(6):748-64.
36. Robert MS, Webster FX, Kiemle D. Solutions Manual for Spectrometric Identification of Organic Compounds.
37. Gabbott P. Fast scanning DSC. Principles and Applications of Thermal Analysis. 2008 Jan 1:51-86.
38. Cullity BD, Stock SR. Elements of X-ray diffraction 3rd ed.
39. Goldstein JI, Newbury DE, Michael JR, Ritchie NW, Scott JH, Joy DC. Scanning electron microscopy and X-ray microanalysis. springer; 2017 Nov 17.
40. Faisal W, Farag F, Abdellatif AA, Abbas A. Taste masking approaches for medicines. Current drug delivery. 2018 Feb 1;15(2):167-85.
41. Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. Journal of controlled release. 2011 Jul 30;153(2):106-16.
42. Guideline IH. Pharmaceutical development. Q8 (2R). As revised in August. 2009 Aug 23;23.
43. O'Donnell K, Kartoglu U. QRM, Knowledge Management, and the Importance of ICH Q9 (R1). Pharm. Technol. 2024 Jul;48:20.
44. Guideline IH. Pharmaceutical quality system. Q10, Current step. 2008 Jun;4.
45. Lincoln JE. Overview of the us fda gmps: Good manufacturing practice (gmp)/quality system (qs) regulation (21 CFR part 820). Journal of validation technology. 2012 Jul 1;18(3):17.
46. Bergum JS, Prescott JK, Tejwani RW, Garcia TP, Clark J, Brown W. Current events in blend and content uniformity. Pharm Eng. 2014 Mar;34(2):1-0.
47. Salminen WF, Wiles ME, Stevens RE. Streamlining nonclinical drug development using the FDA 505 (b)(2) new drug application regulatory pathway. Drug Discovery Today. 2019 Jan 1;24(1):46-56.
48. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D printing of tablets containing multiple drugs with defined release profiles. International journal of pharmaceutics. 2015 Oct 30;494(2):643-50.
49. Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Advanced drug delivery reviews. 2008 Mar 17;60(6):625-37.